Several studies report that these mutations are associated with the sensitivity of NSCLC patients to EGFR tyrosine kinase inhibitors (TKIs) [6,7]; therefore, clinical testing for EGFR mutations has become a standard care for patients with NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.